CLINICAL TRIALS PROFILE FOR PARSACLISIB
✉ Email this page to a colleague
Clinical Trials for Parsaclisib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02018861 ↗ | A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) | Completed | Incyte Corporation | Phase 1/Phase 2 | Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1 inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. Parsaclisib inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells. |
| NCT02718300 ↗ | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | Active, not recruiting | Incyte Corporation | Phase 2 | The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis. |
| NCT02998476 ↗ | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | Completed | Incyte Corporation | Phase 2 | The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma. |
| NCT03039114 ↗ | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) | Active, not recruiting | Incyte Corporation | Phase 1 | The purpose of this study is to evaluate the safety and efficacy of parsaclisib when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL). |
| NCT03126019 ↗ | An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) | Active, not recruiting | Incyte Corporation | Phase 2 | The purpose of this study is to assess the objective response rate of parsaclisib treatment in subjects with relapsed or refractory follicular lymphoma. |
| NCT03144674 ↗ | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | Active, not recruiting | Incyte Corporation | Phase 2 | The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. |
| NCT03235544 ↗ | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) | Active, not recruiting | Incyte Corporation | Phase 2 | This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in subjects with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Parsaclisib
Condition Name
Clinical Trial Locations for Parsaclisib
Trials by Country
Clinical Trial Progress for Parsaclisib
Clinical Trial Phase
Clinical Trial Sponsors for Parsaclisib
Sponsor Name
